ES2699965T3 - Una combinación de rosa de bengala y anticuerpo anti-CTLA4 para su uso en el tratamiento del cáncer - Google Patents

Una combinación de rosa de bengala y anticuerpo anti-CTLA4 para su uso en el tratamiento del cáncer Download PDF

Info

Publication number
ES2699965T3
ES2699965T3 ES12755115T ES12755115T ES2699965T3 ES 2699965 T3 ES2699965 T3 ES 2699965T3 ES 12755115 T ES12755115 T ES 12755115T ES 12755115 T ES12755115 T ES 12755115T ES 2699965 T3 ES2699965 T3 ES 2699965T3
Authority
ES
Spain
Prior art keywords
composition
pharmaceutical composition
intralesional
cancer
systemic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12755115T
Other languages
English (en)
Spanish (es)
Inventor
Craig J Eagle
H Craig Dees
Eric A Wachter
Jamie Singer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Corp Belgium
Pfizer Corp SRL
Provectus Pharmatech Inc
Original Assignee
Pfizer Corp Belgium
Pfizer Corp SRL
Provectus Pharmatech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Corp Belgium, Pfizer Corp SRL, Provectus Pharmatech Inc filed Critical Pfizer Corp Belgium
Application granted granted Critical
Publication of ES2699965T3 publication Critical patent/ES2699965T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ES12755115T 2011-03-10 2012-03-09 Una combinación de rosa de bengala y anticuerpo anti-CTLA4 para su uso en el tratamiento del cáncer Active ES2699965T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161451395P 2011-03-10 2011-03-10
PCT/US2012/028412 WO2012122444A1 (en) 2011-03-10 2012-03-09 Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer

Publications (1)

Publication Number Publication Date
ES2699965T3 true ES2699965T3 (es) 2019-02-13

Family

ID=46798564

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12755115T Active ES2699965T3 (es) 2011-03-10 2012-03-09 Una combinación de rosa de bengala y anticuerpo anti-CTLA4 para su uso en el tratamiento del cáncer

Country Status (9)

Country Link
US (7) US9107887B2 (enExample)
EP (1) EP2710137B1 (enExample)
JP (2) JP6322413B2 (enExample)
KR (1) KR20140038382A (enExample)
CN (1) CN103476943A (enExample)
CA (1) CA2828940C (enExample)
ES (1) ES2699965T3 (enExample)
MX (1) MX360254B (enExample)
WO (1) WO2012122444A1 (enExample)

Families Citing this family (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1797881B1 (en) 2004-09-17 2009-04-15 Eisai R&D Management Co., Ltd. Medicinal composition with improved stability and reduced gelation properties
WO2007015578A1 (ja) * 2005-08-02 2007-02-08 Eisai R & D Management Co., Ltd. 血管新生阻害物質の効果を検定する方法
AU2006309551B2 (en) 2005-11-07 2012-04-19 Eisai R & D Management Co., Ltd. Use of combination of anti-angiogenic substance and c-kit kinase inhibitor
ES2556173T3 (es) * 2006-05-18 2016-01-13 Eisai R&D Management Co., Ltd. Agente antitumoral para un cáncer de tiroides
KR101445892B1 (ko) * 2007-01-29 2014-09-29 에자이 알앤드디 매니지먼트 가부시키가이샤 미분화형 위암 치료용 조성물
CN101848895B (zh) * 2007-11-09 2013-10-23 卫材R&D管理有限公司 血管新生抑制物质和抗肿瘤性铂络合物的组合使用
CA2802644C (en) 2010-06-25 2017-02-21 Eisai R & D Management Co., Ltd. Antitumor agent using compounds having kinase inhibitory effect in combination
CN103476943A (zh) 2011-03-10 2013-12-25 普罗维克图斯药品公司 用于增强治疗癌症的局部和全身性免疫调节疗法的组合
RU2580609C2 (ru) * 2011-04-18 2016-04-10 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Противоопухолевое терапевтическое средство
EP3444363B1 (en) 2011-06-03 2020-11-25 Eisai R&D Management Co., Ltd. Biomarkers for prediciting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
KR102125658B1 (ko) 2012-05-04 2020-06-22 화이자 인코포레이티드 전립선 관련된 항원 및 백신 기재 면역치료 요법
US10034938B2 (en) * 2012-08-30 2018-07-31 Amgen Inc. Method for treating melanoma using a herpes simplex virus and an immune checkpoint inhibitor
AU2013364953A1 (en) 2012-12-21 2015-04-30 Eisai R&D Management Co., Ltd. Amorphous form of quinoline derivative, and method for producing same
TW201427681A (zh) * 2013-01-07 2014-07-16 Superlab Far East Ltd 用空間構象改變的重組干擾素治療腫瘤的方法
US12421502B2 (en) 2013-04-18 2025-09-23 Tilt Biotherapeutics Oy Enhanced adoptive cell therapy
DK3461491T3 (da) 2013-04-18 2025-02-03 Tilt Biotherapeutics Oy Forbedret adoptiv celleterapi
WO2014185540A1 (en) 2013-05-14 2014-11-20 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
CA2939941A1 (en) * 2014-02-21 2015-08-27 Abbvie Stemcentrx Llc Anti-dll3 antibodies and drug conjugates for use in melanoma
PL3134123T3 (pl) * 2014-02-21 2021-07-12 Nektar Therapeutics (India) Pvt. Ltd. Agoniści selektywni względem IL-2Rbeta w kombinacji z przeciwciałem anty-CTLA-4 lub z przeciwciałem anty-PD-1
KR20240144452A (ko) 2014-03-05 2024-10-02 브리스톨-마이어스 스큅 컴퍼니 항-pd-1 항체 및 또 다른 항암제의 조합물을 이용한 신장암의 치료
KR20170003692A (ko) 2014-05-15 2017-01-09 브리스톨-마이어스 스큅 컴퍼니 항-pd-1 항체 및 또 다른 항암제의 조합물을 사용한 폐암의 치료
KR102329681B1 (ko) 2014-08-28 2021-11-23 에자이 알앤드디 매니지먼트 가부시키가이샤 고순도의 퀴놀린 유도체 및 이를 제조하는 방법
WO2016106146A1 (en) 2014-12-23 2016-06-30 The Regents Of The University Of California Methods for immunomodulation of cancer and infectious disease therapy
CN104459129A (zh) * 2015-01-05 2015-03-25 复旦大学附属华山医院 一种鉴别活动性与潜伏性结核分枝杆菌感染的诊断试剂盒
KR20250024102A (ko) 2015-02-25 2025-02-18 에자이 알앤드디 매니지먼트 가부시키가이샤 퀴놀린 유도체의 고미 억제 방법
AU2015384801B2 (en) 2015-03-04 2022-01-06 Eisai R&D Management Co., Ltd. Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
SG11201708223QA (en) 2015-04-17 2017-11-29 Bristol Myers Squibb Co Compositions comprising a combination of an anti-pd-1 antibody and another antibody
KR20250107941A (ko) 2015-04-28 2025-07-14 브리스톨-마이어스 스큅 컴퍼니 항-pd-1 항체를 사용한 pd-l1-양성 흑색종의 치료
KR20170138555A (ko) 2015-04-28 2017-12-15 브리스톨-마이어스 스큅 컴퍼니 항-pd-1 항체 및 항-ctla-4 항체를 사용한 pd-l1-음성 흑색종의 치료
KR101997241B1 (ko) 2015-05-21 2019-07-09 하푼 테라퓨틱스, 인크. 삼중특이성 결합 단백질 및 사용 방법
US20180155429A1 (en) 2015-05-28 2018-06-07 Bristol-Myers Squibb Company Treatment of pd-l1 positive lung cancer using an anti-pd-1 antibody
US11078278B2 (en) 2015-05-29 2021-08-03 Bristol-Myers Squibb Company Treatment of renal cell carcinoma
ES2886107T3 (es) 2015-06-16 2021-12-16 Prism Biolab Co Ltd Antineoplásico
PT3322731T (pt) 2015-07-14 2021-02-25 Bristol Myers Squibb Co Método de tratamento de cancro utilizando inibidor de ponto de verificação (checkpoint) imunitário; anticorpo que se liga ao recetor de morte programada-1 (pd-1) ou ligando de morte programada 1 (pd-l1)
SG11201801083UA (en) 2015-08-20 2018-03-28 Eisai R&D Man Co Ltd Tumor therapeutic agent
CA3004107C (en) 2015-11-11 2023-10-17 Agalimmune Limited Glycolipid compounds and their uses in the treatment of tumours
CN108350081A (zh) 2015-11-18 2018-07-31 百时美施贵宝公司 使用抗pd-1抗体和抗ctla-4抗体的组合治疗肺癌
US10130658B2 (en) 2015-12-18 2018-11-20 Provectus Pharmatech, Inc. Method of ex vivo enhancement of immune cell activity for cancer immunotherapy with a small molecule ablative compound
LT3394093T (lt) 2015-12-23 2022-04-25 Modernatx, Inc. Ox40 ligandus koduojančių polinukleotidų naudojimo būdai
US11209441B2 (en) 2016-04-05 2021-12-28 Bristol-Myers Squibb Company Cytokine profiling analysis
US20190111111A1 (en) * 2016-04-13 2019-04-18 The Regents Of The University Of California Treatment of Cerebral Cavernous Malformations
MX393869B (es) 2016-05-18 2025-03-24 Modernatx Inc Polinucleotidos que codifican interleucina-12 (il12) y usos de los mismos.
JP7194594B2 (ja) 2016-05-18 2022-12-22 モデルナティエックス インコーポレイテッド 免疫調節ポリペプチドをコードするｍＲＮＡの組み合わせ及びその使用
AU2017268399B2 (en) 2016-05-18 2023-01-12 Modernatx, Inc. mRNA combination therapy for the treatment of cancer
JP7169195B2 (ja) 2016-05-20 2022-11-10 バイオヘイブン・ファーマシューティカル・ホールディング・カンパニー・リミテッド 癌を処置するためのリルゾール、リルゾールプロドラッグまたはリルゾール類似体と免疫療法との併用
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
HRP20230864T1 (hr) 2016-06-02 2023-11-10 Bristol-Myers Squibb Company Pd-1 blokada nivolumabom kod refraktornog hodgkinovog limfoma
WO2017210631A1 (en) 2016-06-03 2017-12-07 Bristol-Myers Squibb Company Anti-pd-1 antibody for use in a method of treatment of recurrent small cell lung cancer
CN109476754A (zh) 2016-06-03 2019-03-15 百时美施贵宝公司 抗-pd-1抗体在治疗结肠直肠癌患者中的用途
KR102634093B1 (ko) 2016-10-28 2024-02-07 브리스톨-마이어스 스큅 컴퍼니 항-pd-1 항체를 사용하여 요로상피 암종을 치료하는 방법
AU2018209164B2 (en) 2017-01-17 2021-11-04 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
US12303505B2 (en) 2017-02-08 2025-05-20 Eisai R&D Management Co., Ltd. Tumor-treating pharmaceutical composition
AU2018243754B2 (en) 2017-03-31 2025-04-10 Bristol-Myers Squibb Company Methods of treating tumor
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
KR20190139225A (ko) 2017-04-28 2019-12-17 머크 샤프 앤드 돔 코포레이션 암 치료제용 생물마커
AU2018265856B2 (en) 2017-05-12 2023-04-27 Harpoon Therapeutics, Inc. Mesothelin binding proteins
US20200197384A1 (en) 2017-05-16 2020-06-25 Eisai R&D Management Co., Ltd. Treatment of hepatocellular carcinoma
EP3625246A1 (en) 2017-05-18 2020-03-25 ModernaTX, Inc. Polynucleotides encoding tethered interleukin-12 (il12) polypeptides and uses thereof
CA3060989A1 (en) 2017-05-30 2018-12-06 Bristol-Myers Squibb Company Compositions comprising a combination of an anti-lag-3 antibody, a pd-1 pathway inhibitor, and an immunotherapeutic agent
GB201710097D0 (en) * 2017-06-23 2017-08-09 Univ Ulster A sensitizer - peptide conjugate
CN111386117A (zh) 2017-09-29 2020-07-07 百时美施贵宝公司 治疗癌症的组合物和方法
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
WO2019075359A1 (en) 2017-10-13 2019-04-18 Harpoon Therapeutics, Inc. TRISPECIFIC PROTEINS AND METHODS OF USE
KR20200064132A (ko) 2017-10-15 2020-06-05 브리스톨-마이어스 스큅 컴퍼니 종양을 치료하는 방법
CN111787918A (zh) * 2017-11-29 2020-10-16 洛克菲勒大学 用于皮肤病学病况增强治疗的局部和全身性治疗的组合
WO2019143607A1 (en) 2018-01-16 2019-07-25 Bristol-Myers Squibb Company Methods of treating cancer with antibodies against tim3
EA202091751A1 (ru) 2018-01-22 2020-11-06 Бристол-Маерс Сквибб Компани Композиции и способы лечения рака
EP3768715A1 (en) 2018-03-23 2021-01-27 Bristol-Myers Squibb Company Antibodies against mica and/or micb and uses thereof
WO2019191676A1 (en) 2018-03-30 2019-10-03 Bristol-Myers Squibb Company Methods of treating tumor
ES2964399T3 (es) * 2018-05-16 2024-04-05 Provectus Pharmatech Inc Actividad antitumoral in vitro y xenoinjerto de un xanteno halogenado contra tumores sólidos pediátricos refractarios
WO2019229745A1 (en) 2018-05-27 2019-12-05 Biolinerx Ltd. Agi-134 combined with a checkpoint inhibitor for the treatment of solid tumors
WO2020014583A1 (en) 2018-07-13 2020-01-16 Bristol-Myers Squibb Company Ox-40 agonist, pd-1 pathway inhibitor and ctla-4 inhibitor combination for use in a mehtod of treating a cancer or a solid tumor
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
BR112021005769A2 (pt) 2018-09-25 2021-07-06 Harpoon Therapeutics Inc proteínas de ligação a dll3 e métodos de uso
KR20210081384A (ko) 2018-10-23 2021-07-01 브리스톨-마이어스 스큅 컴퍼니 종양을 치료하는 방법
US20220001026A1 (en) 2018-11-08 2022-01-06 Modernatx, Inc. Use of mrna encoding ox40l to treat cancer in human patients
AU2019379325B2 (en) 2018-11-16 2025-04-24 Genexine, Inc. Method of treating a tumor with a combination of IL-7 protein and an immune checkpoint inhibitor
KR20210092769A (ko) 2018-11-16 2021-07-26 브리스톨-마이어스 스큅 컴퍼니 항-nkg2a 항체 및 그의 용도
WO2020109328A1 (en) 2018-11-26 2020-06-04 Debiopharm International S.A. Combination treatment of hiv infections
GB201819853D0 (en) * 2018-12-05 2019-01-23 Innovation Ulster Ltd Therapy
JP7625521B2 (ja) 2018-12-28 2025-02-03 トランスジーン ｍ２欠陥ポックスウイルス
WO2020198672A1 (en) 2019-03-28 2020-10-01 Bristol-Myers Squibb Company Methods of treating tumor
WO2020198676A1 (en) 2019-03-28 2020-10-01 Bristol-Myers Squibb Company Methods of treating tumor
CN114127315A (zh) 2019-05-30 2022-03-01 百时美施贵宝公司 鉴定适合于免疫肿瘤学(i-o)疗法的受试者的方法
WO2020243570A1 (en) 2019-05-30 2020-12-03 Bristol-Myers Squibb Company Cell localization signature and combination therapy
KR20220016156A (ko) 2019-05-30 2022-02-08 브리스톨-마이어스 스큅 컴퍼니 면역-종양학 요법에의 적합성을 위한 다종양 유전자 시그너쳐
GB201912107D0 (en) 2019-08-22 2019-10-09 Amazentis Sa Combination
US20220348653A1 (en) 2019-09-22 2022-11-03 Bristol-Myers Squibb Company Quantitative Spatial Profiling for LAG-3 Antagonist Therapy
WO2021092220A1 (en) 2019-11-06 2021-05-14 Bristol-Myers Squibb Company Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
WO2021092221A1 (en) 2019-11-06 2021-05-14 Bristol-Myers Squibb Company Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
BR112022008191A2 (pt) 2019-11-08 2022-07-12 Bristol Myers Squibb Co Terapia com antagonista de lag-3 para melanoma
MX2022005828A (es) * 2019-11-19 2022-07-04 Provectus Pharmatech Inc Composicion y metodo para tratamiento de canceres hematologicos.
US11419844B2 (en) 2019-11-19 2022-08-23 Provectus Pharmatech, Inc. Halogenated xanthene composition and method for treating hematologic cancers
US12064507B2 (en) 2019-11-19 2024-08-20 Provectus Pharmatech, Inc. Composition and method for oral treatment of leukemia
EP4076529A1 (en) 2019-12-19 2022-10-26 Bristol-Myers Squibb Company Combinations of dgk inhibitors and checkpoint antagonists
JP2023514152A (ja) 2020-02-06 2023-04-05 ブリストル－マイヤーズ スクイブ カンパニー Ｉｌ－１０およびその使用
CA3172124A1 (en) * 2020-03-26 2021-09-30 Aru NARENDRAN Uses of halogenated xanthenes in oncology and virology
US11938182B2 (en) 2020-03-26 2024-03-26 Provectus Pharmatech, Inc. Halogenated xanthenes as vaccine adjuvants
WO2021243207A1 (en) 2020-05-28 2021-12-02 Modernatx, Inc. Use of mrnas encoding ox40l, il-23 and il-36gamma for treating cancer
AU2021331476A1 (en) 2020-08-28 2023-05-04 Bristol-Myers Squibb Company Lag-3 antagonist therapy for hepatocellular carcinoma
KR20230061430A (ko) 2020-08-31 2023-05-08 브리스톨-마이어스 스큅 컴퍼니 세포 국재화 시그너쳐 및 면역요법
IL301907A (en) 2020-10-23 2023-06-01 Bristol Myers Squibb Co Lag-3 antagonist therapy for lung cancer
WO2022120179A1 (en) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Multi-tumor gene signatures and uses thereof
SI4267105T1 (sl) 2020-12-28 2025-07-31 Bristol-Myers Squibb Company Sestave protiteles in načini njihove uporabe
CA3196999A1 (en) 2020-12-28 2022-07-07 Masano HUANG Methods of treating tumors
JP2024514530A (ja) 2021-04-02 2024-04-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 切断型ｃｄｃｐ１に対する抗体およびその使用
CN118176214A (zh) 2021-10-29 2024-06-11 百时美施贵宝公司 血液癌症的lag-3拮抗剂疗法
KR20240135661A (ko) 2022-01-26 2024-09-11 브리스톨-마이어스 스큅 컴퍼니 간세포성 암종에 대한 조합 요법
WO2023161453A1 (en) 2022-02-24 2023-08-31 Amazentis Sa Uses of urolithins
CA3251366A1 (en) 2022-02-25 2023-08-31 Bristol Myers Squibb Co POLYTHERAPY AGAINST COLORECTAL CARCINOMA
WO2023168404A1 (en) 2022-03-04 2023-09-07 Bristol-Myers Squibb Company Methods of treating a tumor
CN119156403A (zh) 2022-03-08 2024-12-17 阿伦蒂斯治疗股份公司 抗紧密连接蛋白-1抗体增加t细胞可用性的用途
US20250206775A1 (en) 2022-03-18 2025-06-26 Bristol-Myers Squibb Company Methods of isolating polypeptides
WO2023196987A1 (en) 2022-04-07 2023-10-12 Bristol-Myers Squibb Company Methods of treating tumor
WO2023196988A1 (en) 2022-04-07 2023-10-12 Modernatx, Inc. Methods of use of mrnas encoding il-12
WO2023213764A1 (en) 2022-05-02 2023-11-09 Transgene Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
WO2023213763A1 (en) 2022-05-02 2023-11-09 Transgene Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
CA3258064A1 (en) 2022-06-02 2023-12-07 Bristol Myers Squibb Co ANTIBODY COMPOSITIONS AND THEIR METHODS OF USE
KR20250034101A (ko) 2022-07-01 2025-03-10 트랜스진 계면활성제-단백질-d 및 tnfsf의 구성원을 포함하는 융합 단백질
WO2024040175A1 (en) 2022-08-18 2024-02-22 Pulmatrix Operating Company, Inc. Methods for treating cancer using inhaled angiogenesis inhibitor
CN120731228A (zh) 2022-12-21 2025-09-30 百时美施贵宝公司 肺癌的组合疗法
WO2024196952A1 (en) 2023-03-20 2024-09-26 Bristol-Myers Squibb Company Tumor subtype assessment for cancer therapy
WO2025038763A1 (en) 2023-08-15 2025-02-20 Bristol-Myers Squibb Company Ceramic hydroxyapatite chromatography flow through method
US20250215087A1 (en) 2023-12-29 2025-07-03 Bristol-Myers Squibb Company Combination therapy of kras inhibitor and treg depleting agent
WO2025184208A1 (en) 2024-02-27 2025-09-04 Bristol-Myers Squibb Company Anti-ceacam5 antibodies and uses thereof
WO2025184211A1 (en) 2024-02-27 2025-09-04 Bristol-Myers Squibb Company Anti-ceacam5 antibody drug conjugates
WO2025202222A1 (en) 2024-03-25 2025-10-02 Institut National de la Santé et de la Recherche Médicale Therapeutic use of sting and tlrs agonists to induce p16 expression in immune cells
WO2025245489A1 (en) 2024-05-24 2025-11-27 Bristol-Myers Squibb Company Treatment of tumors in subjects having fgl-1 positive samples

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2553131B1 (fr) * 1983-10-11 1986-02-21 Ydais Pierre Ensemble d'elements modulaires permettant la realisation de volumes de rangement et plus particulierement de caves, d'abris de jardin
US5725855A (en) * 1991-04-05 1998-03-10 The United States Of America As Represented By The Department Of Health And Human Services Method of treating tumors with CD8+ -depleted or CD4+ T cell subpopulations
US6689757B1 (en) * 1996-02-12 2004-02-10 M.L. Laboratories Plc Methods for vaccination and vaccines therefor
US8557298B2 (en) 1998-08-06 2013-10-15 Provectus Pharmatech, Inc. Medicaments for chemotherapeutic treatment of disease
US20090117199A1 (en) 1998-08-06 2009-05-07 Scott Timothy C Method of treatment of cancer
US7648695B2 (en) 1998-08-06 2010-01-19 Provectus Pharmatech, Inc. Medicaments for chemotherapeutic treatment of disease
US20020001567A1 (en) * 1998-12-21 2002-01-03 Photogen, Inc. Intracorporeal medicaments for high energy phototherapeutic treatment of disease
PT1535622E (pt) * 1999-04-08 2009-03-19 Schering Corp Terapia de melanoma
ATE406157T1 (de) * 1999-08-13 2008-09-15 Provectus Pharmatech Inc Verbesserte topische medikamente sowie verfahren zur photodynamischer behandlung von krankheiten
AU2003272361A1 (en) 2002-09-11 2005-04-11 Sequenom, Inc. Methods for identifying subjects at risk of melanoma and treatments thereof
US7378233B2 (en) 2003-04-12 2008-05-27 The Johns Hopkins University BRAF mutation T1796A in thyroid cancers
US20050019918A1 (en) 2003-06-03 2005-01-27 Hidetoshi Sumimoto Treatment of cancer by inhibiting BRAF expression
EP1541695A1 (en) 2003-12-09 2005-06-15 Nanogen Recognomics GmbH Use of a mutation in the BRAF gene for the determination of the malignancy of melanoma cells
WO2005110388A1 (en) * 2004-05-10 2005-11-24 Hofmann Robert F Use of targeted oxidative therapeutic formulation in treatment of cancer
GB0423554D0 (en) 2004-10-22 2004-11-24 Cancer Rec Tech Ltd Therapeutic compounds
CN101052655A (zh) 2004-11-04 2007-10-10 辉瑞产品有限公司 用于治疗乳腺癌的ctla4抗体和芳香酶抑制剂组合物
GB0428082D0 (en) 2004-12-22 2005-01-26 Welcome Trust The Ltd Therapeutic compounds
US7442507B2 (en) 2005-01-24 2008-10-28 New York University School Of Medicine Methods for detecting circulating mutant BRAF DNA
EP1863532A1 (en) 2005-03-23 2007-12-12 Pfizer Products Incorporated Anti-ctla4 antibody and indolinone combination therapy for treatment of cancer
US8110194B2 (en) * 2005-12-07 2012-02-07 Medarex, Inc. CTLA-4 antibody dosage escalation regimens
CA2647282A1 (en) 2006-04-05 2007-10-11 Pfizer Products Inc. Ctla4 antibody combination therapy
WO2007125330A1 (en) 2006-04-26 2007-11-08 Cancer Research Technology Limited Imidazo[4, 5-b]pyridin-2-one and oxazolo[4, 5-b]pyridin-2-one compounds and analogs thereof as cancer therapeutic compounds
US7897762B2 (en) 2006-09-14 2011-03-01 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of proliferative diseases
CA2639416C (en) * 2007-09-11 2019-12-31 F. Hoffmann-La Roche Ag Diagnostic test for susceptibility to b-raf kinase inhibitors
EA019974B1 (ru) 2007-12-19 2014-07-30 Кансер Рисерч Текнолоджи Лимитед 8-ЗАМЕЩЕННЫЕ ПИРИДО[2,3-b]ПИРАЗИНЫ И ИХ ПРИМЕНЕНИЕ
WO2010014784A2 (en) * 2008-08-01 2010-02-04 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
RU2636046C2 (ru) * 2009-01-12 2017-11-17 Сайтомкс Терапьютикс, Инк Композиции модифицированных антител, способы их получения и применения
TW201041888A (en) 2009-05-06 2010-12-01 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
EP2947098B1 (en) * 2009-07-20 2019-11-20 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with gemcitabine for the synergistic treatment of proliferative diseases
KR101494055B1 (ko) * 2009-09-18 2015-02-16 프로벡투스 파마슈티컬스 인코포레이티드 4,5,6,7-테트라클로로-3'',6''-다이하이드록시-2'',4'',5'',7''- 테트라요오도-3ｈ-스피로［이소벤조푸란-1,9''-잔텐］-3-온(로즈 벤갈) 및 관련 잔텐의 합성 방법
CN103476943A (zh) 2011-03-10 2013-12-25 普罗维克图斯药品公司 用于增强治疗癌症的局部和全身性免疫调节疗法的组合

Also Published As

Publication number Publication date
US10471144B2 (en) 2019-11-12
EP2710137A1 (en) 2014-03-26
US11071781B2 (en) 2021-07-27
WO2012122444A1 (en) 2012-09-13
US20150290165A1 (en) 2015-10-15
US9107887B2 (en) 2015-08-18
MX2013010340A (es) 2013-11-01
US20150290309A1 (en) 2015-10-15
JP6322413B2 (ja) 2018-05-09
US20200138942A1 (en) 2020-05-07
US9839688B2 (en) 2017-12-12
CA2828940C (en) 2024-04-16
CA2828940A1 (en) 2012-09-13
US9808524B2 (en) 2017-11-07
MX360254B (es) 2018-10-26
CN103476943A (zh) 2013-12-25
US20120263677A1 (en) 2012-10-18
US20180055926A1 (en) 2018-03-01
JP2014510728A (ja) 2014-05-01
EP2710137B1 (en) 2018-09-19
US20220008534A1 (en) 2022-01-13
JP2018109036A (ja) 2018-07-12
KR20140038382A (ko) 2014-03-28
US20150290318A1 (en) 2015-10-15
EP2710137A4 (en) 2014-12-31

Similar Documents

Publication Publication Date Title
ES2699965T3 (es) Una combinación de rosa de bengala y anticuerpo anti-CTLA4 para su uso en el tratamiento del cáncer
Hong et al. Intratumoral immunotherapy for early-stage solid tumors
Chakraborty et al. Application of toll-like receptors (TLRs) and their agonists in cancer vaccines and immunotherapy
Luo et al. Synergistic STING activation by PC7A nanovaccine and ionizing radiation improves cancer immunotherapy
Wang et al. Nanomaterials for combinational radio–immuno oncotherapy
ES2703826T3 (es) Inmunoterapia con IL-12 destinada al cáncer
Yang et al. Toll-like receptor-targeted anti-tumor therapies: Advances and challenges
ES2409755T3 (es) Método para Tratar el Cáncer Utilizando un Agente Anticanceroso Combinado
Le Naour et al. Trial watch: Toll-like receptor ligands in cancer therapy
BR112015018989B1 (pt) Combinação de vacina/inibidor da via de pd-1, inibidor da via de pd-1 e vacina de rna
ES2924138T3 (es) Nueva composición farmacéutica que comprende partículas que comprenden un complejo de un polirribonucleótido de doble cadena y una polialquilenimina
BR122021025267B1 (pt) Partes de kit e composição farmacêutica compreendendo um inibidor da via de pd-1
Qin et al. CD19-targeted HSP90 inhibitor nanoparticle combined with TKIs reduces tumor burden and enhances T-cell immunity in murine B-cell malignancies
He et al. Decitabine/paclitaxel co-delivery systems modified with anti-PD-L1 antibodies mediate chemoimmunotherapy for Triple negative breast cancer
Peng et al. The emerging nanomedicine-based technology for non-small cell lung cancer immunotherapy: how far are we from an effective treatment
ES2966116T3 (es) Composiciones para modular la transducción de señales PD-1
CA3042889A1 (en) Non-adult human dosing of anti-cd30 antibody-drug conjugates
Zhu et al. Current progresses of functional nanomaterials for imaging diagnosis and treatment of melanoma
Zhao et al. Polymersome-enabled brain Codelivery of STAT3 siRNA and CpG oligonucleotide boosts chemo-immunotherapy of malignant glioma
Chen et al. Nanomedicine based on chemotherapy-induced immunogenic death combined with immunotherapy to enhance antitumor immunity
Kota et al. Prophylactic and therapeutic cancer vaccine with continuous localized immunomodulation
Tayebi-Khorrami et al. Immune checkpoint blocking in cancer therapy using thermosensitive hydrogels: a review
Gu et al. Novel'Stereoscopic response'strategy can be used in combination therapy
HK1192589A (en) Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer
Nadella et al. Macrophages directed approaches are paramount for effective cancer immunotherapies